Background: Genetic variation in the VWF gene is associated with von Willebrand fac-
| INTRODUCTION
Von Willebrand disease occurs when there is a defect in the quantity or quality of von Willebrand factor. Many cases are due to genetic defects in the VWF gene, but other patients have VWD without an identified associated VWF genetic defect. Genetic changes in VWF are clearly linked to type 2 VWD where specific genetic defects in regions of the VWF gene coding for specific functional domains of the protein cause predictable defects due to the location. 1 For example, type 2B
VWD genetic defects map to exon 28, which encodes for the VWF A1
domain responsible for binding GPIb. Type 2N VWD genetic defects map to the D′D3 region which binds factor VIII (FVIII). Many patients with type 3 VWD, where the VWF protein is absent, have been found to have homozygosity or compound heterozygosity for VWF genetic changes coding for stop codons or large deletions in the VWF gene. 2, 3 In type 1 VWD, the most common VWD variant, sequence variants are spread across the VWF gene, with no particular predilection for a specific location. 1 Occasionally heterozygosity for type 3 VWD variants such as large deletions are seen, but missense mutations make up the vast majority of type 1 VWD sequence variants. 2 When VWF gene sequencing is performed in type 1 VWD, only about 2/3 of patients are found to have genetic variants that might account for their low VWF levels. 4 This percentage has held relatively stable across several large studies of type 1 VWD. [5] [6] [7] [8] Lower VWF levels are in general more likely to be associated with a genetic variant. 6, 7 Other genes outside the VWF locus have been implicated in altering VWF levels, such as ABO and CLEC4M. 9, 10 While much work has been done on deleterious genetic variants that decrease VWF, there are potential variants that increase VWF levels as well. The CHARGE Consortium reported on a number of variants in both FVIII and VWF. 11 Recently, Johnsen and colleagues reported on VWF variants in African Americans associated with higher VWF and FVIII levels. 12 Because the D′D3 region contains the only binding site for FVIII found in VWF, we focused on variants found in this region. These include synonymous variants c.2880G>A (p.Arg960=) 12, 13 and c.2385C>T
(p.Tyr795=) 12, 13 and nonsynonymous variant c.2365A>G (p.Thr789Ala). 12 We hypothesized that such variants might be under-represented in patients diagnosed with type 1 VWD, where a mild decrease in VWF level is typically present, by conferring an increase in VWF level.
| METHODS
Subjects were enrolled in the Zimmerman Program for the Molecular and Clinical Biology of VWD as previously described. 14 Informed consent was obtained from all subjects or their guardian if the subject was under age 18. Healthy control subjects 18 and older were recruited from participating centers via advertisement and were included if they were over the age of 18 and willing to complete study enrollment. VWD subjects were enrolled at clinic visit and through advertisement at some centers. Exclusion criteria included a pre-existing diagnosis of VWD. Specific attempts were made to enroll diverse ethnic groups. Healthy control subjects reported bleeding symptoms and donated a single blood sample for VWF testing and genetic analysis.
VWD subjects reported bleeding symptoms and donated a blood sample at the time of enrollment, but were also eligible for follow-up visits (not addressed here). Participants self-identified race and ethnicity, but were given the option to decline answering. Sanger sequencing of the full length VWF gene, including intron and exon boundaries, was performed as previously described. 15 VWF antigen was performed by ELISA assay, VWF ristocetin cofactor activity was performed by automated agglutination, and FVIII levels were obtained via one stage clotting assay as previously described. 14 VWF propeptide was measured by ELISA as previously described. 16 ABO blood group was assigned by detection of isohemagglutinins. 9 Bleeding score was calculated using the ISTH bleeding assessment tool. 17 Only subjects with data available for all categories were analyzed. Sample size was determined based on the total number of subjects enrolled during the course of the study.
Subjects were divided into cohorts based on their underlying diagnosis. Healthy controls were adult subjects recruited as controls with no previous diagnosis of a bleeding disorder or VWD. Type 1 VWD subjects were those with a VWF:Ag and/or VWF:RCo <30 IU/dL at the time of study enrollment. Type 2 VWD subjects had laboratory findings consistent with the type 2 VWD variant in question. Type 3 VWD subjects had undetectable VWF (either at study entry or on a historical sample if the study entry sample was obtained while on treatment).
Expression of VWF sequence variants was performed using sitedirected mutagenesis as previously described. 18 
Essentials
• Specific sequence variants in the VWF D′D3 region are associated with elevated VWF antigen levels.
• VWF levels and variant frequencies were examined in both European and Caucasian Americans.
• Subjects homozygous for D′D3 variants had the highest VWF and factor VIII levels.
• D′D3 variants are less frequent in type 1 VWD, suggesting a potential protective effect. 
| RESULTS
VWF parameters, FVIII activity levels, and VWF gene sequencing were tested for a group of healthy control subjects and a group of type 1 VWD subjects enrolled in a larger study of VWD, the Zimmerman Program.
| VWF c.2880G>A
We first looked at 256 healthy control subjects and compared those with or without VWF c.2880G>A. Healthy control subjects with c.2880G>A had higher mean VWF:Ag (149 IU/dL) and FVIII (116 IU/dL) whereas healthy control subjects lacking this variant had lower mean VWF:Ag (107 IU/dL) and FVIII (103 IU/dL) as shown in Figure 1 . This difference was statistically significant (P < .001) for both VWF:Ag and FVIII. Since our healthy controls had a higher number of African American subjects, we also compared VWF and FVIII levels by race. As expected, the c.2880G>A
variant was more common in African Americans (61% of controls)
as compared to European Americans (36% of controls). Of the African American controls, 52% were heterozygous and 9% were homozygous for c.2880G>A, while of the European Americans, 30%
were heterozygous and 7% were homozygous for c.2880G>A. An association of high VWF levels with these variants was observed in both the European American only group and African American only group, with presence of c.2880G>A associated with higher mean VWF levels (P < .001). There was no significant difference in FVIII (P = NS). This allele was also observed at high frequencies in the ExAC database, including in European (25%) and African (31%)
ancestries (Table 1) . variant, the difference in VWF:Ag was significant (P < .05 for African Americans, P < .001 for European Americans). No difference however was observed in mean FVIII levels (P = NS). Both VWF variants were observed at nearly identical high frequencies (consistent 
| Type 1 VWD
We then looked at the prevalence of these VWF variants in 97 type 1 VWD subjects with VWF:Ag or VWF:RCo <30 IU/dL. As shown in table 2, VWF c.2880G>A was significantly more common in controls (36% European American, 61% African American) than in subjects diagnosed with type 1 VWD (20%, P < .005). VWF c.2365A>G(;) c.2385T>C was significantly more common in controls (49% European American, 88% African American) than in subjects diagnosed with type 1 VWD (35%, P < .001). VWF:Ag, VWF:RCo, and FVIII levels were not statistically different in type 1 VWD subjects who had these VWF D′D3 region variants compared to type 1 VWD patients without them ( Figure 3 ). The bleeding score also did not differ significantly between those with and without the variants under study. For VWF c.2880G>A, the median bleeding score was 7 for those subjects with the variant as compared to 6 for those without (P = NS). For VWF c.2365A>G(;)c.2385T>C, the median bleeding score was 7 for those subjects with the variant as compared to 5 for those without (P = NS).
VWF variant frequencies were similar to healthy controls for subjects with a historical diagnosis of type 1 VWD but current VWF:Ag >50 or with a diagnosis of type 2 VWD. However, the frequencies of each variant in those subjects with type 1 VWD and levels 30-50 IU/dL was similar to those with levels <30 IU/dL (20% for c.2880G>A and 38% for c.2365A>G(;)c.2385T>C).
There is an association of low VWF with blood group O. 9 In our type 1 subjects, however, there was no difference in ABO blood group frequency when subjects with the D′D3 region variants were compared to those without the variants.
To investigate the possible effect of these variants on production and clearance of VWF, we also examined VWF propeptide (excluding 
| Allele effect and effect size
The number of subjects homozygous for either variant was small, but there was a trend towards an allele effect, with the highest VWF and FVIII levels in subjects homozygous for c.2880G>A or homozygous for c.2365A>G(;)c.2385T>C (Table 2) . Heterozygotes for either variant combination had intermediate levels, while those homozygous for the VWF "wild-type" reference allele had the lowest VWF and FVIII levels. Table 3 shows the VWF levels observed in subjects homozygous and heterozygous for these variants. Both homozygous and heterozygous subjects had significantly higher levels compared to wild-type with the exception of c.2880G>A homozygotes (who were small in number) for FVIII and propeptide levels.
On average, VWF and FVIII levels were higher by about 50% in subjects homozygous for either set of VWF variants. There were fewer subjects with these variants in the type 1 VWD group, when compared with the control group. Based on the prevalence of these variants in the control population, about 15% more type 1 VWD subjects would have been expected to have these variants, suggesting that the presence of one or more of these variants protects against a diagnosis of VWD.
| Secretion and function of recombinant VWF variants
In an effort to determine the effect of each specific variant, recom- c.2385T>C variants were always found together, consistent with linkage disequilibrium. A priori, the c.2365A>G change was evaluated to be most likely to be a causative variant since it is nonsynonymous, but in vitro expression of this variant alone did not result in a significant increase in VWF levels. The c.2880G>A variant was independently associated with higher VWF levels despite being synonymous.
| DISCUSSION
The frequencies of both VWF c.2880G>A and c.2365A>G(;) c.2385T>C were reduced in type 1 VWD, suggesting that subjects with these VWF alleles are less likely to be diagnosed with type 1 VWD. A similar pattern was seen in subjects who had VWF:Ag ranging from 30-50 IU/dL. In type 1 VWD, no difference in bleeding score was seen between subjects with or without these variants. This suggests that the variants may affect VWF (and FVIII) levels but do not directly affect bleeding symptoms. Subjects enrolled in the Zimmerman Program with type 2A or type 2B VWD had these higher VWF-associated VWF variants at frequencies comparable to the control group rather than the type 1 VWD group. This is consistent with the known mechanisms of the type 2 VWD subtypes, which are defined by functionally defective VWF proteins rather than quantitatively low (but functionally normal) VWF levels. Thus, common VWF polymorphisms associated with increased overall VWF levels would not be expected to rescue the qualitative functional defects that define type 2 VWD disease phenotypes.
There is evidence that sequence variants in VWF can affect VWF levels via clearance, and therefore lead to reduced VWF survival, with the clearest example p.R1205H, or the Vicenza variant. 20 There is evidence that sequence variations in other genes can affect VWF levels, with the strongest cases currently for ABO blood group 9 and CLEC4M, which binds and clears VWF. 10, 21 It therefore seems reasonable that other variation within or outside VWF could confer increased VWF levels, either by directly increasing VWF expression, by prolonging survival, or by influencing interactions with other VWF modifiers.
FVIII levels in circulation are in large part dependent on the presence of VWF. Type 3 VWD patients have low FVIII simply because the VWF is not present to protect circulating FVIII. Acquired elevations in VWF are also accompanied by elevations in FVIII, such as after demopressin challenge. 22 Higher VWF levels due to VWF genetic variation can be expected to be associated with higher levels of FVIII.
African Americans in general have higher VWF and FVIII levels. 12, 23, 24 Higher VWF and/or FVIII levels are also associated with thrombosis. All data are given in IU/dL and represent the mean ± 1 SD. *P < 0.005 as compared to wild-type. **P < 0.05 as compared to wild-type.
Consistent with this, the VWF c.2365G>A variant has been associated with deep vein thrombosis. 25 We did not find evidence that these variants directly increase VWF secretion in vitro and genomic computational tools find these positions to be poorly conserved. It is possible that these variants do not impact protein or transcript function directly (Table 1) . However the in vivo propeptide data suggest that either synthesis is increased, given the higher antigen levels, or survival is increased, given the lower VWFpp/VWF:Ag ratios (Table 3) . It is also possible that these variants mark VWF alleles with functional genetic elements that influence VWF levels but lie outside of the VWF gene regions sequenced in this study. VWF, and so in the case of these variants increased VWF levels would presumably lead to an increase in total FVIII binding capacity. 29 There may also be other variants associated with the haplotype containing the D′D3 region variants.
The strengths of this study include the ability to compare variant frequencies and VWF levels in both healthy individuals and in a well-defined cohort of subjects with type 1 VWD and the ability to functionally test recombinant expression of naturally occurring VWF DNA variants in vitro. There are some limitations, however, in the retrospective study design and relatively small number of homozygous subjects available for study. In addition, the control population does not necessarily represent the demographics of the general population of type 1 VWD, although efforts were made to obtain good representation of all races.
In conclusion, specific sequence variants in VWF are associated with higher VWF and FVIII levels. These variants may protect against quantitative decreases in VWF levels and a diagnosis of type 1 VWD. The genetic diagnosis of type 1 VWD remains complicated, and may require consideration of the effect of multiple sequence variants within VWF.
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